DIVO vs IBB
Amplify CWP Enhanced Dividend Income ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.56% for DIVO.
- • DIVO pays a higher dividend yield (2.26%).
Side-by-side metrics
| Metric | DIVO | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.56% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.26% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $7.19B | $9.09B |
YTD return | 6.37% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.56 | 0.69 |
P/E ratio | 24.83 | 24.79 |
Last price | $46.29 | $196.62 |
Inception | — | — |
Issuer | Amplify | iShares |
DIVO top holdings
| CAT | Caterpillar Inc | 6.98% |
| AAPL | Apple Inc | 5.10% |
| MSFT | Microsoft Corp | 4.93% |
| JPM | JPMorgan Chase & Co | 4.86% |
| GS | The Goldman Sachs Group Inc | 4.59% |
| AXP | American Express Co | 4.52% |
| TJX | TJX Companies Inc | 4.43% |
| SOFR | Amplify Samsung SOFR ETF | 4.31% |
| AMGN | Amgen Inc | 4.19% |
| CME | CME Group Inc Class A | 3.98% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About DIVO
DIVO (Amplify CWP Enhanced Dividend Income ETF) is Quality dividend payers with tactical covered calls. Managed by Amplify, the fund carries $7.2B in assets under management, an expense ratio of 0.56%, a dividend yield of 2.26%. Its largest holding is Caterpillar Inc (CAT), which represents 7.0% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 11.4%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.